[Due to normal transaminase values, no further treatment. Hepatitis C patient "suddenly" has liver cirrhosis].
D000998:Antiviral Agents / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005188:False Negative Reactions; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000175:diagnosis* / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000188:drug therapy / Q000201:enzymology; D008111:Liver Function Tests; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins; D012016:Reference Values; D012254:Ribavirin / Q000008:administration & dosage; D000637:Transaminases / Q000097:blood*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000637:Transaminases; C100416:peginterferon alfa-2a